Research Team

Jacob Borodovsky, PhD

Senior Research Scientist, Center for Technology and Behavioral Health and the Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth

Opioids; Buprenorphine; Marijuana; Cannabis; Epidemiology; Policy


Contact

Jacob Borodovsky, PhD
Senior Research Scientist, Center for Technology and Behavioral Health and the Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth

46 Centerra Parkway, Suite 300-301
, Lebanon, NH 03766

Jacob.T.Borodovsky@dartmouth.edu


Selected Publications
  • Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. PMID: 24953168; PMCID: PMC4180514.
  • Schuman-Olivier Z, Connery H, Griffin ML, Wyatt SA, Wartenberg AA, Borodovsky J, Renner JA Jr, Weiss RD. Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013 Nov-Dec;22(6):574-80. doi: 10.1111/j.1521-0391.2013.12024.x. PMID: 24131165; PMCID: PMC3801272.
  • Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug Alcohol Depend. 2013 Oct 1;132(3):580-6. doi: 10.1016/j.drugalcdep.2013.04.006. PMID: 23688843; PMCID: PMC3916951.